Quick Answer
Valion Bio, Inc. reported Total Revenue of $780.0 thousand for fiscal year 2024.
Valion Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $780.0K -33.7% |
$1.18M -36.1% |
$1.84M +46.4% |
$1.26M | — |
| Net Income | -$8.88M -57.0% |
-$5.66M +31.4% |
-$8.24M +18.3% |
-$10.10M -18.9% |
-$8.49M | — |
| Diluted EPS | — | -$19.68 +88.9% |
-$176.80 -69.5% |
-$104.32 -4193.0% |
-$2.43 | — |
| Total Assets | $31.61M +1026.0% |
$2.81M -45.6% |
$5.16M -12.2% |
$5.88M -60.9% |
$15.04M | — |
| Cash and Equivalents | $12.64M +531.6% |
$2.00M -41.0% |
$3.40M -3.5% |
$3.52M -72.9% |
$12.97M | — |
| Stockholders Equity | $3.31M +30.7% |
$2.54M -29.2% |
$3.58M -1.4% |
$3.63M -72.6% |
$13.27M +1227.6% |
-$1.18M |
| R&D Expense | $3.13M +138.5% |
$1.31M -20.7% |
$1.66M -4.3% |
$1.73M +97.0% |
$878.0K | — |
| Operating Income | -$7.90M -76.5% |
-$4.48M +45.7% |
-$8.24M +18.4% |
-$10.10M -79.3% |
-$5.63M | — |
| Gross Profit | — | $2.0K -99.3% |
$287.0K -4.0% |
$299.0K +886.8% |
-$38.0K | — |
| Shares Outstanding | 2.53M +353.5% |
556,902 +545.8% |
86,241 -10.9% |
96,778 -99.0% |
9.72M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $146.0K | +15.9% | +69.8% |
| Revenue (ASC 606) | September 30, 2025 | $146.0K | +15.9% | +15.9% |
| Net Income | September 30, 2025 | -$2.60M | -81.4% | -34.4% |
| Diluted EPS | June 30, 2025 | -$2.19 | +59.2% | +13.1% |
| Total Assets | September 30, 2025 | $6.23M | +83.5% | +38.2% |
| Cash and Equivalents | September 30, 2025 | $3.45M | +57.6% | +191.4% |
| Stockholders Equity | September 30, 2025 | $5.59M | +97.3% | +51.6% |
| R&D Expense | September 30, 2025 | $858.0K | +103.3% | +31.0% |
| Operating Income | September 30, 2025 | -$2.48M | -73.5% | -28.4% |
| Gross Profit | September 30, 2025 | -$145.0K | -429.5% | -368.5% |
| Shares Outstanding | September 30, 2025 | 1.66M | -73.4% | +72.2% |
- Valion Bio, Inc. reported Total Revenue of $780.0 thousand for fiscal year 2024.
- Valion Bio, Inc. showed a decrease of -33.7% in Total Revenue compared to the prior fiscal year.
- Valion Bio, Inc. reported Net Income of -$8.88 million for fiscal year 2025.
- Valion Bio, Inc. showed a decrease of -57.0% in Net Income compared to the prior fiscal year.
- Valion Bio, Inc. reported Diluted EPS of $19.68 per share (loss) for fiscal year 2024.
- Valion Bio, Inc. showed an increase of +88.9% in Diluted EPS compared to the prior fiscal year.
- Valion Bio, Inc. reported Total Assets of $31.61 million for fiscal year 2025.
- Valion Bio, Inc. showed an increase of +1026.0% in Total Assets compared to the prior fiscal year.
- Valion Bio, Inc. reported Cash and Equivalents of $12.64 million for fiscal year 2025.
- Valion Bio, Inc. showed an increase of +531.6% in Cash and Equivalents compared to the prior fiscal year.
- Valion Bio, Inc. reported Stockholders Equity of $16.80 million for fiscal year 2025.
- Valion Bio, Inc. showed an increase of +392.0% in Stockholders Equity compared to the prior fiscal year.
- Valion Bio, Inc. reported R&D Expense of $3.13 million for fiscal year 2025.
- Valion Bio, Inc. showed an increase of +138.5% in R&D Expense compared to the prior fiscal year.
- Valion Bio, Inc. reported Operating Income of -$7.90 million for fiscal year 2025.
- Valion Bio, Inc. showed a decrease of -76.5% in Operating Income compared to the prior fiscal year.
- Valion Bio, Inc. reported Gross Profit of $2.0 thousand for fiscal year 2024.
- Valion Bio, Inc. showed a decrease of -99.3% in Gross Profit compared to the prior fiscal year.
- Valion Bio, Inc. reported Shares Outstanding of 2.53 million shares for fiscal year 2025.
- Valion Bio, Inc. showed an increase of +353.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: